Clinical Trial Update: Curative Effect Evaluation of Danlou Tablet on Coronary Artery Disease Not Amenable to Revascularization [Phase 4]

View source ↗

Summary

Danlou Tablet is being evaluated in a Phase 4 trial for its curative effect on coronary artery disease not amenable to revascularization.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Danlou Tablet

Snippet

Sponsor: Jun Li | Conditions: Coronary Artery Disease(CAD) | Phase 4 | Status: UNKNOWN